Trial Profile
A Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Subjects With Epilepsy With a Predictable Seizure Pattern
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Oct 2022
Price :
$35
*
At a glance
- Drugs Alprazolam (Primary)
- Indications Epilepsy; Generalised epilepsy; Generalised seizures; Partial epilepsies
- Focus Therapeutic Use
- Acronyms StATES
- Sponsors Engage Therapeutics
- 12 Oct 2022 Results of Phase 2b study assessing the efficacy of alprazolam for rapid seizure termination in patients with seizure episodes with a predictable pattern published in the Epilepsia
- 08 Dec 2020 Results from part 2 portion of this phase 2b assessing efficacy, feasibility and safety of STAP treatment in patients with predictable seizure patterns presented at the 74th Annual Meeting of the American Epilepsy Society
- 01 May 2020 Topline Results from Part 2 (data cut off: 4 October 2019; n=74) presented at the 72nd Annual Meeting of the American Academy of Neurology